Hangzhou Nuohui Health Technology Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Hangzhou Nuohui Health Technology Co., Ltd. - overview
Established
2015
Location
Hangzhou, Zhejiang, China
Primary Industry
Healthcare
About
Hangzhou Nuohui Health Technology Co. , Ltd. specializes in innovative cancer screening solutions, focusing on early detection through advanced diagnostic technologies and home testing products. Founded in 2015, Hangzhou Nuohui Health Technology Co.
, Ltd. is dedicated to developing and providing early cancer screening solutions. The company is headquartered in Hangzhou, China. The founders Yeqing Zhu and Yiyou Chen have led the company through various growth phases.
As of February 18, 2021, the company completed an IPO, raising HKD 2. 0421 billion. NuoHui Health offers a range of diagnostic products, including liquid biopsy tests that facilitate non-invasive cancer detection. These products are designed to improve patient outcomes by enabling early intervention and are targeted towards healthcare providers and individual consumers.
The company intends to expand its offerings internationally, addressing a growing demand for reliable cancer screening solutions. In the most recent year, 2021, NuoHui Health reported a revenue of HKD 32,978,182. 30 and an EBITDA of HKD -476,696,641. 10.
The company's revenue is primarily generated through direct-to-consumer sales and partnerships with healthcare facilities, focusing on diagnostic tests and home testing kits. Following its IPO on February 18, 2021, in which it raised HKD 2. 0421 billion, Hangzhou Nuohui Health Technology Co. , Ltd.
plans to utilize these funds to support the development of new diagnostic products and expand into international markets. The company is targeting expansion into North America and Europe, aiming for growth in these regions by 2023.
Current Investors
Legend Capital, SB China Venture Capital, Zhejiang Pudu Technology
Primary Industry
Healthcare
Sub Industries
Diagnostic, Medical & Imaging Laboratories, Oncology/Cancer Treatment, Diagnostic Equipment
Website
www.newhorizonbio.com
Verticals
HealthTech
Company Stage
Mature
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.